Axsome jumps after Takeda balipodect acquisition, ahead of April 30 FDA catalyst
Axsome Therapeutics shares rose about 3% Wednesday as investors reacted to its deal to acquire global rights to Takeda’s balipodect, a PDE10A inhibitor. The move also reflects optimism into the April 30, 2026 FDA decision date for Auvelity’s expanded use in Alzheimer’s agitation.
1. What’s moving the stock
Axsome Therapeutics (AXSM) traded higher Wednesday, aligning with reports that the company has struck an agreement to acquire global rights from Takeda to balipodect, an oral selective PDE10A inhibitor being positioned for neuropsychiatry indications including schizophrenia and Tourette syndrome. The market is treating the asset as a pipeline broadener in central nervous system (CNS) disease, with management indicating Phase 3 trial-enabling activities targeted to begin in 2026. (benzinga.com)
2. Why it matters now
The incremental enthusiasm comes as Axsome approaches a major near-term regulatory catalyst: an FDA action date of April 30, 2026 for an Auvelity expansion into agitation associated with dementia of the Alzheimer’s type (often referenced as Alzheimer’s disease agitation). With the PDUFA clock in view, positive pipeline headlines and supportive analyst commentary can have outsized impact on daily trading. (investing.com)
3. What investors will watch next
Key next steps include clearer disclosure on the total economics of the Takeda balipodect transaction (upfront payment, milestones, and royalties) and any updated development timelines as Axsome advances Phase 3 preparation. Separately, positioning into the April 30 FDA decision is likely to remain a dominant driver of sentiment and volatility for AXSM through the remainder of April. (benzinga.com)